Announcement • Jul 29
IQVIA Holdings Inc. Provides Earnings Guidance for the Third Quarter of 2026 IQVIA Holdings Inc. provided earnings guidance for the third quarter of 2026. For the third quarter, the company expects revenue to be between $4.315 billion and $4.390 billion which represents year-over-year growth of 5.2% to 7.1%. Reported Earnings • Jul 28
Second quarter 2026 earnings released: EPS: US$1.54 (vs US$1.55 in 2Q 2025) Second quarter 2026 results: EPS: US$1.54 (down from US$1.55 in 2Q 2025). Revenue: US$4.37b (up 8.7% from 2Q 2025). Net income: US$256.0m (down 3.8% from 2Q 2025). Profit margin: 5.9% (down from 6.6% in 2Q 2025). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 9.7% growth forecast for the Life Sciences industry in Europe. Announcement • Jul 28
IQVIA Holdings Inc. Raises Earnings Guidance for the Year 2026 IQVIA Holdings Inc. raised earnings guidance for the year 2026. For the year, the company is raising its full-year 2026 guidance for revenue to be between $17,275 million and $17,475 million. Valuation Update With 7 Day Price Move • Jul 28
Investor sentiment improves as stock rises 20% After last week's 20% share price gain to €212, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 27% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €334 per share. Announcement • Jul 09
IQVIA Holdings Inc. to Report Q2, 2026 Results on Jul 28, 2026 IQVIA Holdings Inc. announced that they will report Q2, 2026 results Pre-Market on Jul 28, 2026 Valuation Update With 7 Day Price Move • Jun 25
Investor sentiment improves as stock rises 15% After last week's 15% share price gain to €164, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 20x in the Life Sciences industry in Europe. Total returns to shareholders of 21% over the past year. Simply Wall St's valuation model estimates the intrinsic value at €270 per share. Announcement • May 07
IQVIA Holdings Inc. Reaffirms Earnings Guidance for the Full-Year 2026 IQVIA Holdings Inc. reaffirmed earnings guidance for the full-year 2026. For the year, the company expects revenue to be between $17,150 million and $17,350 million. Reported Earnings • May 06
First quarter 2026 earnings released: EPS: US$1.63 (vs US$1.42 in 1Q 2025) First quarter 2026 results: EPS: US$1.63 (up from US$1.42 in 1Q 2025). Revenue: US$4.15b (up 8.4% from 1Q 2025). Net income: US$274.0m (up 10.0% from 1Q 2025). Profit margin: 6.6% (up from 6.5% in 1Q 2025). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.8% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Board Change • Apr 30
Insufficient new directors There is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 5 highly experienced directors. Independent Director Bill Kaelin was the last director to join the board, commencing their role in 2025. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Apr 16
IQVIA Holdings Inc. to Report Q1, 2026 Results on May 05, 2026 IQVIA Holdings Inc. announced that they will report Q1, 2026 results Pre-Market on May 05, 2026 Announcement • Mar 02
IQVIA Holdings Inc., Annual General Meeting, Apr 23, 2026 IQVIA Holdings Inc., Annual General Meeting, Apr 23, 2026. Location: hotel zero degrees, 15 milestone road, conneticut 06810, danbury, United States New Risk • Feb 12
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Italian stocks, typically moving 5.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (17% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (5.8% average weekly change). Reported Earnings • Feb 06
Full year 2025 earnings released: EPS: US$7.91 (vs US$7.57 in FY 2024) Full year 2025 results: EPS: US$7.91. Revenue: US$16.3b (up 5.9% from FY 2024). Net income: US$1.36b (flat on FY 2024). Profit margin: 8.3% (down from 8.9% in FY 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.6% p.a. on average during the next 3 years, compared to a 9.5% growth forecast for the Life Sciences industry in Europe. Announcement • Feb 05
IQVIA Holdings Inc. Provides Earnings Guidance for Full Year 2026 IQVIA Holdings Inc. provided earnings guidance for full year 2026. For the full year of 2026, the company expects revenue to be between $17,150 million to $17,350 million. This
revenue guidance assumes about 150 basis points of contribution from acquisitions and approximately 100 basis points tailwind from foreign exchange. Valuation Update With 7 Day Price Move • Feb 04
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to €167, the stock trades at a forward P/E ratio of 25x. Average forward P/E is 15x in the Life Sciences industry in Europe. Simply Wall St's valuation model estimates the intrinsic value at €256 per share. Announcement • Jan 21
IQVIA Holdings Inc. to Report Q4, 2025 Results on Feb 05, 2026 IQVIA Holdings Inc. announced that they will report Q4, 2025 results Pre-Market on Feb 05, 2026 Announcement • Nov 06
IQVIA Appoints William G. Kaelin Jr. to its board of directors, Effective November 5, 2025 IQVIA announced the appointment of Dr. William G. Kaelin Jr. to its board of directors, effective November 5, 2025. Dr. Kaelin is a Senior Physician-Scientist at Brigham and Women’s Hospital in Boston and the Sidney Farber Professor of Medicine at the Dana-Farber Cancer Institute and Harvard Medical School. He is also an Investigator at the Howard Hughes Medical Institute. In 2019, Dr. Kaelin was awarded the Nobel Prize in Physiology or Medicine for his groundbreaking work on oxygen sensing and the role of the von Hippel-Lindau (VHL tumor) suppressor protein. He currently serves on the board of directors of Eli Lilly and Company, where he chairs the Science and Technology Committee. Dr. Kaelin is the recipient of numerous prestigious prizes and honors in addition to the Nobel Prize, including the Albert Lasker Basic Medical Research Award, the Wiley Prize in Biomedical Sciences from Rockefeller University, the Paul Marks Prize for Cancer Research from the Memorial Sloan Kettering Cancer Center and the Canada Gairdner Internal Award. He is the author of hundreds of peer-reviewed publications and holds multiple patents related to cancer biology and hypoxia signaling. Dr. Kaelin holds a Doctor of Medicine from Duke University School of Medicine and a Bachelor of Arts in Mathematics and Associate Bachelor in Chemistry from Duke University. Reported Earnings • Oct 29
Third quarter 2025 earnings released: EPS: US$1.95 (vs US$1.57 in 3Q 2024) Third quarter 2025 results: EPS: US$1.95 (up from US$1.57 in 3Q 2024). Revenue: US$4.10b (up 5.2% from 3Q 2024). Net income: US$331.0m (up 16% from 3Q 2024). Profit margin: 8.1% (up from 7.3% in 3Q 2024). The increase in margin was driven by higher revenue. Revenue is forecast to grow 5.3% p.a. on average during the next 3 years, compared to a 9.6% growth forecast for the Life Sciences industry in Europe. Announcement • Oct 28
IQVIA Holdings Inc. Reaffirms Earnings Guidance for the Full Year 2025 IQVIA Holdings Inc. reaffirmed earnings guidance for the full year 2025. For the year,the company is reaffirming the midpoint of its full-year 2025 guidance and narrowing the ranges revenue expected to be between $16,150 million and $16,250 million. Board Change • Oct 27
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 6 highly experienced directors. Independent Director Leslie Morris was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Oct 01
IQVIA Holdings Inc. to Report Q3, 2025 Results on Oct 28, 2025 IQVIA Holdings Inc. announced that they will report Q3, 2025 results Pre-Market on Oct 28, 2025 Announcement • Sep 12
Iqvia Announces Launch of Clinical Trial Financial Suite, A Next-Generation Platform for Integrated Financial Management IQVIA announced the launch of its Clinical Trial Financial Suite (CTFS), an AI-enabled platform implementing all financial aspects of clinical trials. CTFS is designed to eliminate inefficiencies created by siloed systems and fragmented processes. In contrast to other industry offerings, CTFS unifies budgeting, contracting, forecasting and payment workflows with shared data and end-to-end processes. The suite's first module, CTFS Site Payments, brings end-to-end automation to one of the most complex trial processes. By leveraging agentic AI to set up budgets, process invoices and identify anomalies, the module gives up financial teams from repetitive manual tasks to focus their attention more productively. IQVIA's technology and operations experts behind CTFS have supported site and participant payments across more than 200 geographies. The solution uses advanced technology to deliver enterprise-grade scalability and security, while deploying AI to drive efficiency and acceleration to the most manual and burdensome processes. Projected customer outcomes include up to 50% reduction in processing time. Reported Earnings • Jul 22
Second quarter 2025 earnings released: EPS: US$1.55 (vs US$1.99 in 2Q 2024) Second quarter 2025 results: EPS: US$1.55 (down from US$1.99 in 2Q 2024). Revenue: US$4.02b (up 5.3% from 2Q 2024). Net income: US$266.0m (down 27% from 2Q 2024). Profit margin: 6.6% (down from 9.5% in 2Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Life Sciences industry in Europe. Announcement • Jul 22
IQVIA Holdings Inc. Updates Earnings Guidance for the Full Year 2025 IQVIA Holdings Inc. updated earnings guidance for the full year 2025. For the year, the company now expects revenue between $16,100 million and $16,300 million. This revenue guidance assumes approximately $100 million of COVID-related revenue step-down, entirely in R&DS, approximately 100 basis points of tailwind from foreign exchange, and approximately 150 basis points of contribution from acquisitions. Announcement • Jul 02
IQVIA Holdings Inc. to Report Q2, 2025 Results on Jul 22, 2025 IQVIA Holdings Inc. announced that they will report Q2, 2025 results Pre-Market on Jul 22, 2025 Board Change • Jun 20
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 5 highly experienced directors. Independent Director Leslie Morris was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. Announcement • Jun 11
IQVIA Launches New AI Agents for Life Sciences and Healthcare IQVIA unveiled AI agents at GTC Paris. IQVIA’s new custom-built AI agents using NVIDIA technology are designed to enhance workflows and accelerate insights for life sciences. These live applications of agentic architectures illustrate how IQVIA AI and deep domain expertise are transforming business processes and patient outcomes. While IQVIA Healthcare-grade AI has been delivering insights with the precision, speed and trust required for the life sciences industry across the asset life cycle, this recent collaboration with NVIDIA represents an exciting new phase as we advance the powerful future promised by agentic AI in a way that meets the unique needs of life sciences companies. Leveraging NVIDIA NIM Agent Blueprints for rapid development, the NeMo Customizer for fine-tuning, and NeMo Guardrails to safeguard deployment, IQVIA is developing agents that help find breakthroughs and simplify operations across life sciences. Use cases for these agentic offerings include target identification, clinical data review, literature review, market assessment, and HCP engagement. Announcement • May 27
IQVIA Holdings Inc. Announces First Patient Dosed in Renew Phase 2 Trial of Lti-03 in Patients with Ipf IQVIA Holdings Inc. announced that the first patient has been dosed in the RENEW Phase 2 trial of its lead asset, LTI-03, a novel, multi-pathway, Caveolin-1-related peptide for the treatment of IPF. Rein's second product candidate, LTI-01, is a proenzyme that has completed Phase 1b and Phase 2a clinical trials for the treatment of loculated pleural effusions. LTI-01 has received Orphan Drug Designation in the U.S. and E.U. and Fast Track Designation in the U.s. Reported Earnings • May 07
First quarter 2025 earnings released: EPS: US$1.42 (vs US$1.58 in 1Q 2024) First quarter 2025 results: EPS: US$1.42 (down from US$1.58 in 1Q 2024). Revenue: US$3.83b (up 2.5% from 1Q 2024). Net income: US$249.0m (down 14% from 1Q 2024). Profit margin: 6.5% (down from 7.7% in 1Q 2024). The decrease in margin was driven by higher expenses. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe. Board Change • May 06
Insufficient new directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 5 highly experienced directors. Independent Director Leslie Morris was the last director to join the board, commencing their role in 2022. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model. 
